Drug
Obudanersen
Obudanersen: highest development phase Phase 3, developed by Ionis Pharmaceuticals. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Ionis Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| obudanersen NCT07782827 | Phase 3 | Angelman Syndrome |
| obudanersen NCT06914609 | Phase 3 | Angelman Syndrome |
Latest
No recent events.
Follow Obudanersen on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.